Background
Exos
The biogenesis of Exos
The isolation and characterization of Exos
Exos based periodontitis diagnostic and treatment strategy
Exos-based periodontitis diagnostic strategy
Exos-based periodontitis treatment strategy
Source of Exos | Study model | Route of delivery | Dose | Duration | Outcomes | References |
---|---|---|---|---|---|---|
MSCs | Mouse experimental periodontitis model | Locally injection | 50 μg per mouse | 14 days | Improve the treatment by restoring the Th17 cell/Treg balance through the miR-1246/Nfat5 axis | [46] |
DPSCs | Mouse experimental periodontitis model | Incorporated chitosan hydrogel | 50 μg | 4 weeks | Facilitate macrophages from M1 to M2 phenotype and promote alveolar bone healing | [47] |
HHH-DPSCs | Mouse experimental periodontitis model | Directly applied onto the silk ligature | 5 μL containing 7.5 × 108 particles | 7 days | Promote the migration of both DPCs and osteoblastic cells; suppress osteoclast formation | [48] |
PDLSCs | Rat periodontal bone defect model | Mixed with Matrigel | Exos (225 μg/μL): Matrigel = 2:1 (v/v) | 4 weeks | Suppress overactivation Wnt signaling, recover osteogenic differentiation capacity of inflammatory PDLSCs | [49] |
TNF-α-treated human GMSCs | Mouse experimental periodontitis model | Locally injection | 20 μg per mouse | 7 days | Regulate inflammation and osteoclastogenesis | [50] |
SHED | Mouse experimental periodontitis model | Locally injection | 20 μg | 2 weeks | Restore bone loss, promote BMSCs osteogenesis, differentiation, and bone formation | [51] |
SHED | Rat periodontal defect models | h β-TCP scaffffolds loaded with Exos | 2 μg/μL Exos in 100 μL PBS | 4 weeks | Contribute to periodontal bone regeneration through the AMPK signaling pathway | [52] |
induced M2-like macrophages | Mouse experimental periodontitis model | Locally injection | 30 μL (500 ng/ml) | 2 weeks | Reduce alveolar bone resorption in mice with periodontitis via IL-10/IL-10R pathway | [53] |
ADSCs | Rat experimental periodontitis model | Locally injection | 80–150 µg in 200 µL PBS | 4 weeks | Represent a promising adjunctive treatment to SRP | [54] |
salivary Exos | Insulin resistance-associated mouse experimental periodontitis model | Locally injection | miR-25-3p inhibitors (100 μl of 8 nM) | 9 days | Exosomal miR-25-3p in saliva contribute to development and progression of diabetes-associated periodontitis | [55] |
Possible mechanism of Exos on host cells during periodontitis
Effects of Exos on neutrophils
Effects of Exos on macrophages
Effects of Exos on DCs
Effects of Exos on T lymphocytes
Effects of Exos on B lymphocytes
Effects of Exos on osteoclasts
No | Source of Exos | Biological activity | References |
---|---|---|---|
Neutrophil | |||
1 | MSCs | Have protective effects on neutrophil function and lifespan | [56] |
2 | MSCs | Reduce terminal complement activation complex C5b-9 to inhibit neutrophils accumulation | [57] |
3 | ADSCs | Decrease neutrophils apoptosis and increased their phagocytosis capacity | [58] |
4 | LPS-treated macrophages | Induce cytokine production and neutrophil migration | [59] |
Macrophage | |||
1 | DPSCs | Facilitate macrophages to convert from M1 phenotype to M2 phenotype | [47] |
2 | TNF-α induced GMSCs | Induce anti-inflammatory M2 macrophage polarization | [50] |
3 | MSCs | Modify the polarization of M1 macrophages to M2 macrophages via shuttling miR-182 | [60] |
4 | BMSCs | Increase M2 macrophage polarization | [61] |
5 | BMSCs | Inhibit M1 polarization and promotes M2 polarization in a murine alveolar macrophage cell line by inhibiting cellular glycolysis | [62] |
6 | FNDC5 pre-conditioned BMSCs | Play anti-inflammation effects and promote M2 macrophage polarization via NF-κB signaling pathway and Nrf2/HO-1 axis | [63] |
7 | hUCMSCs | Facilitate CD163 + M2 macrophage polarization, reduced inflammation, and increases anti-inflammatory responses | [64] |
8 | hUCMSCs | Inhibit M1 polarization and promoted M2 polarization through tumor necrosis factor receptor-associated factor 1 (TRAF1) | [65] |
9 | ADSCs | Upregulate mRNA expression of M2 macrophages | [66] |
10 | ADSCs | Induce anti-inflammatory M2 phenotypes through the transactivation of arginase-1 by Exo-carried active STAT3 | [67] |
11 | ADSCs | Polarize macrophage to an anti-inflammatory phenotype via regulating the Nrf2/HO-1 expression | [68] |
12 | GMSCs | Facilitate macrophages to convert from M1 phenotype to M2 phenotype | [69] |
Dendritic cell | |||
1 | MSCs | Decrease DC surface marker expression and modulates DC-induced immune responses | [70] |
2 | hUCMSCs | Suppress maturation and activation of DCs, and decreases the expression level of IL-23 | [71] |
3 | regDCs | Suppress maturation of recipient DCs resulting in inhibition of bone resorptive cytokines | [72] |
4 | LECs | Promote the directional migratory in a CX3CL1/fractalkine-dependent fashion | [73] |
T lymphocyte | |||
1 | MSCs | Increase Treg cell populations, inhibit T lymphocyte proliferation in a dose-dependent manner and decreases the percentage of CD4 + and CD8 + T cell subsets | [74] |
2 | MSCs | Upregulate IL-10 and TGF-β1 to promote proliferation and immune-suppression capacity of Tregs | [75] |
3 | MSCs | Inhibit the differentiation of Th2 cells via the regulation of the miR-146a-5p/SERPINB2 pathway | [76] |
4 | PDLSCs | Alleviate inflammatory microenvironment and keep Th17/Treg balance via Th17/Treg/miR‐155‐5p/SIRT1 regulatory network | [77] |
5 | CD137-modified ECs | Promote Th17 cell differentiation via NF-КB pathway mediated IL-6 expression | [78] |
B lymphocyte | |||
1 | MSCs | Upregulate Breg-like cells in lymph nodes | [74] |
Osteoclast | |||
1 | TNF-α-preconditioned GMSCs | Inhibit osteoclastogenic activity via exosomal miR-1260b to target Wnt5a-mediated RANKL pathway and | [50] |
2 | regDC | Result in inhibition of bone resorptive cytokines and reduces in osteoclastic bone loss | [72] |
3 | CMS-treated BMSCs | Impair osteoclast differentiation via inhibiting the RANKL-induced nuclear factor kappa-B (NF-κB) signaling pathway | [79] |
4 | ADSCs | Suppress NLRP3 inflammasome activation in osteoclasts and reduces bone resorption and recover bone loss | [80] |
5 | ADSCs | Antagonize osteocyte-mediated osteoclastogenesis | [81] |
6 | ADSCs | Inhibit pro-inflammatory cytokines production in high glucose-treated osteoclasts and restrains bone resorption | [82] |
7 | osteoblast | Inhibit the osteoclast differentiation via miR-503-3p/Hpse axis | [83] |
8 | EPCs | Promote bone repair by enhancing recruitment and differentiation of osteoclast precursors through LncRNA-MALAT1 | (84) |